Meta-analysis of randomized controlled trials of warfarin and aspirin for primary prevention of stroke in atrial fibrillation

Comparison	Stroke		Major bleeding
Comparison	Odds ratio, 95% CI	p value	Odds ratio, 95 percent CI	p value
Conventional dose warfarin versus placebo	0.31 (0.19 to 0.50)	<0.001	1.88 (0.88 to 4.0)	0.10
Aspirin versus placebo	0.68 (0.46 to 1.02)	0.06	0.82 (0.37 to 1.78)	>0.2
Conventional dose warfarin versus aspirin	0.66 (0.45 to 0.99)	0.04	1.61 (0.75 to 3.44)	>0.2
Conventional dose warfarin versus low dose warfarin	0.52 (0.25 to 1.08)	0.08	2.21 (0.67 to 7.25)	0.19
Conventional dose warfarin versus low dose warfarin plus aspirin	0.44 (0.14 to 1.39)	0.16	1.14 (0.55 to 2.36)	>0.2
Low dose warfarin versus aspirin	1.01 (0.49 to 2.06)	>0.2	1.04 (0.43 to 2.48)	>0.2

Warfarin_and_aspirin_in_AF.htm

NOTE: The data in this table cannot be directly applied to clinical practice (an individual patient) since the decision to use warfarin or aspirin is importantly related to a patient's estimated risk of embolic events.

Adapted from McNamara RL, Tamariz LJ, Segal JB, Bass EB. Ann Intern Med 2004; 139:1018.

Graphic 66736 Version 2.0

خرید پکیج

Meta-analysis of randomized controlled trials of warfarin and aspirin for primary prevention of stroke in atrial fibrillation